Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 2Sarcoma 1Head & Neck 1Genitourinary 1Breast 1

Conditions

Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Neoplasm Metastasis 2Endometrial Neoplasms 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1High Grade Serous Carcinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinosarcoma 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Specimen Handling 43pembrolizumab 42Biopsy 36Magnetic Resonance Spectroscopy 34Paclitaxel 21Carboplatin 21Gemcitabine 20Nivolumab 19Irinotecan 17Radiosurgery 15Cisplatin 13Taxes 11Pemetrexed 11Ipilimumab 11Fluorouracil 11Cetuximab 11trastuzumab deruxtecan 10olaparib 10Leucovorin 10130-nm albumin-bound paclitaxel 10abemaciclib 9Oxaliplatin 9Cyclophosphamide 9Capecitabine 9Bevacizumab 9palbociclib 8durvalumab 8Fulvestrant 8X-Rays 7Trastuzumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × ceralasertib × 90 days × Clear all
NCT04704661 2026-05-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

National Cancer Institute (NCI)

Phase 1 Active not recruiting
51 enrolled
BreastGastrointestinalGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03682289 2026-04-23

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

University of California, San Francisco

Phase 2 Active not recruiting
83 enrolled
GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡